学术探索
学术期刊
新闻热点
数据分析
智能评审

Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis

被引：160
作者：
Marty, FM
Yeh, WW
Wennersten, CB
Venkataraman, L
Albano, E
Alyea, EP
Gold, HS
Baden, LR
Pillai, SK
机构：
[1] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Div Med Oncol, Boston, MA 02115 USA
[3] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL MICROBIOLOGY | 2006年 / 44卷 / 02期
关键词：
D O I：
10.1128/JCM.44.2.595-597.2006
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The emergence of a clinically daptomycin-resistant Staphylococcus aureus isolate occurred during treatment of methicillin-resistant S. aureus bacteremia and probable vertebral osteomyelitis. The breakthrough isolate was indistinguishable from pretreatment daptomycin-susceptible isolates by pulsed-field gel electrophoresis. Daptomycin nonsusceptibility was confirmed by MIC and time-kill curve analyses.
引用
收藏
页码：595 / 597
页数：3
相关论文
共 17 条
[1]   The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections [J].
Arbeit, RD ;
Maki, D ;
Tally, FP ;
Campanaro, E ;
Eisenstein, BI .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (12) :1673-1681
[2]   Daptomycin: Another novel agent for treating infections due to drug-resistant gram-positive pathogens [J].
Carpenter, CF ;
Chambers, HF .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (07) :994-1000
[3]  
Clinical and Laboratory Standards, 2005, PERF STAND ANT SUSC
[4]  
*CTR DRUG EV RES F, 2003, 21572 NDA
[5]  
*CUB PHARM INC, 2003, POST DAT CUB
[6]   In vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin against a challenge panel of staphylococci and enterococci, including vancomycin-intermediate Staphylococcus aureus and vancomycin-resistant Enterococcus faecium [J].
Jevitt, LA ;
Smith, AJ ;
Williams, PP ;
Raney, PM ;
McGowan, JE ;
Tenover, FC .
MICROBIAL DRUG RESISTANCE, 2003, 9 (04) :389-393
[7]   Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model [J].
LaPlante, KL ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) :4665-4672
[8]   COMPARATIVE-EVALUATION OF DAPTOMYCIN (LY146032) AND VANCOMYCIN IN THE TREATMENT OF EXPERIMENTAL METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS OSTEOMYELITIS IN RABBITS [J].
MADER, JT ;
ADAMS, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (05) :689-692
[9]   Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia [J].
Mangili, A ;
Bica, I ;
Snydman, DR ;
Hamera, DH .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (07) :1058-1060
[10]  
Maslow Joel N., 1993, P563
12